Post compares PRME's cure capabilities favorably to MRNA, though lacks detailed supporting evidence or clinical data. Key risks include unsubstantiated claims, biotech volatility, and clinical trial uncertainties.

Investor placing £300k into PRME (Primerica/Prime-related genomics play), betting on AI-driven biotech sector breakout led by Cathie Wood's genomics holdings for rare disease cures. Key risks include speculative positioning in emerging AI biotech theme, sector concentration, and valuation sustainability.